By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Blueprint Medicines 



Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Blueprint Medicines (BPMC) Announces New Data From Ongoing Phase I Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma 9/11/2017 6:55:31 AM
Blueprint Medicines (BPMC) To Present Updated Data From Ongoing Phase I Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma At ESMO 2017 Congress And 11th ILCA Annual Conference 8/22/2017 6:46:46 AM
Blueprint Medicines (BPMC) Reports Second Quarter 2017 Financial Results 8/2/2017 12:40:14 PM
Blueprint Medicines (BPMC) To Report Second Quarter 2017 Financial Results On Wednesday, August 2, 2017 7/26/2017 10:23:32 AM
Blueprint Medicines (BPMC) Announces New Phase I Clinical Data For BLU-285 In Advanced Gastrointestinal Stromal Tumors And Plans To Pursue Expedited Development In Patients With A PDGFRa D842V Mutation 6/5/2017 6:45:07 AM
Blueprint Medicines (BPMC) Reports First Quarter 2017 Financial Results 5/3/2017 10:27:24 AM
Blueprint Medicines (BPMC) To Report First Quarter 2017 Financial Results On Wednesday, May 3, 2017 4/26/2017 10:50:19 AM
Blueprint Medicines (BPMC) Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares Of Common Stock 4/5/2017 6:51:46 AM
Blueprint Medicines (BPMC) Announces Proposed Public Offering Of Shares of Common Stock 3/29/2017 8:39:52 AM
Blueprint Medicines (BPMC) Announces Enrollment Of First Patient In Phase 1 Clinical Trial For BLU-667 3/21/2017 6:32:21 AM
123456789
//-->